GURU.Markets stock price, segment price, and overall market index valuation
The company's share price AVDL
Avadel Pharmaceuticals is a biopharmaceutical company focused on the treatment of sleep disorders. Its stock price is heavily dependent on the commercial success of its lead drug, Lumryz, and its competition with other drugs on the market.
Share prices of companies in the market segment - Pharma psycho
Avadel Pharmaceuticals is a biopharmaceutical company focused on treating sleep disorders. We classify it in the Pharma Psychotherapy sector, and the chart below shows the dynamics of the entire segment, as well as the commercial success story of its lead drug, Lumryz.
Broad Market Index - GURU.Markets
Avadel Pharmaceuticals is an Irish biopharmaceutical company developing drugs for the treatment of sleep disorders, particularly narcolepsy. It is a component of the GURU.Markets index. The chart below shows the US market. See how Avadel shares compare to the US market trend.
Change in the price of a company, segment, and market as a whole per day
AVDL - Daily change in the company's share price AVDL
Avadel Pharmaceuticals shares exhibit high volatility, measured by change_co. This reflects sensitivity to regulatory decisions and the commercial success of its drugs. This metric is a key component of the formulas on System.GURU.Markets for analyzing the pharmaceutical sector.
Daily change in the price of a set of shares in a market segment - Pharma psycho
Avadel Pharmaceuticals plc is a pharmaceutical company. This chart highlights the sector's high volatility. Comparing it to AVDL, which focuses on sleep disorders, helps assess its risk relative to more diversified pharmaceutical companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Avadel is a pharmaceutical company specializing in sleep disorders. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Avadel's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization AVDL
Avadel is a biopharmaceutical company specializing in the treatment of diseases of the central nervous system. Its year-over-year performance reflects both the commercial success of its existing drugs and investor confidence in its R&D platform.
Annual dynamics of market capitalization of the market segment - Pharma psycho
Avadel Pharmaceuticals plc is a pharmaceutical company focused on treating sleep disorders. Its success depends on the commercialization of its key drug. The chart shows how its battle for market share with competitors and regulatory decisions impact its volatile performance in a narrow therapeutic niche.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Avadel is a biopharmaceutical company whose stock performance is driven by the success of its drug sales and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization AVDL
Avadel, a biopharmaceutical company whose main product is designed to treat narcolepsy, is a leading cause of death. The monthly fluctuations on the chart reflect the drug's commercial success and its competition with other treatments for this rare disease.
Monthly dynamics of market capitalization of the market segment - Pharma psycho
Avadel Pharmaceuticals is a pharmaceutical company specializing in the development of drugs for the treatment of central nervous system disorders, particularly narcolepsy. The chart below illustrates the overall dynamics of the biotech sector, where the successful approval of one drug can dramatically change a company's fortunes.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Avadel Pharmaceuticals plc is a biopharmaceutical company focused on the treatment of sleep disorders, particularly narcolepsy. The company's future depends on the commercial success of its drugs. The broader market chart serves only as a backdrop to illustrate how its struggle for share in a niche but competitive market and regulatory news have driven its stock price movement completely independently.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization AVDL
Avadel Pharmaceuticals' weekly performance reflects the battle for control of the narcolepsy drug market. This biopharmaceutical company's stock price has reacted sharply to FDA decisions, patent disputes, and the commercial launch of its flagship drug.
Weekly dynamics of market capitalization of the market segment - Pharma psycho
Neuroscience-focused pharmaceuticals are a sector where weekly performance depends on regulatory decisions and commercial success. The battle for the narcolepsy drug market is a common challenge. The chart provides this backdrop against which Avadel's position can be assessed.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Avadel Pharmaceuticals is a biopharmaceutical company. Its success depends on the results of clinical trials and the commercialization of its drugs. This chart will help you understand: does Avadel live in its own world of scientific news, or are the general market conditions and risk appetite in biotech actually influencing its stock price?
Market capitalization of the company, segment and market as a whole
AVDL - Market capitalization of the company AVDL
Avadel's market capitalization chart tells the story of the long and arduous battle for FDA approval of its drug for the treatment of narcolepsy. Its sharp rise on the chart is a narrative of triumph over regulatory and patent obstacles. Its dynamics reflect the market's assessment of the drug's commercial potential, which could change patients' lives.
AVDL - Share of the company's market capitalization AVDL within the market segment - Pharma psycho
Avadel Pharmaceuticals is a biopharmaceutical company focused on the treatment of sleep disorders, particularly narcolepsy. Its market share reflects the potential of its new drug. The chart shows how the company strives to offer patients a new standard of care that could change their lives.
Market capitalization of the market segment - Pharma psycho
Avadel Pharmaceuticals is a biopharmaceutical company focused on the treatment of sleep disorders, particularly narcolepsy. The chart below shows the overall market capitalization of this sector. Its dynamics provide the backdrop against which Avadel is commercializing its product, seeking to offer patients a new therapeutic option.
Market capitalization of all companies included in a broad market index - GURU.Markets
Avadel Pharmaceuticals has developed a once-daily treatment for narcolepsy. Its market capitalization is based on the commercial potential of this more convenient medication. The chart below shows the economic weight of companies improving existing treatments.
Book value capitalization of the company, segment and market as a whole
AVDL - Book value capitalization of the company AVDL
Avadel Pharmaceuticals' balance sheet represents its capital, supporting the commercialization of its innovative drug for the treatment of narcolepsy. Its book value reflects the tangible, scientific, and commercial foundation aimed at changing the lives of patients. How has this asset changed since approval? The chart below illustrates this transformation.
AVDL - Share of the company's book capitalization AVDL within the market segment - Pharma psycho
Avadel Pharmaceuticals uses specialized pharmaceutical facilities to manufacture its drugs, including those for narcolepsy. The chart shows the share of these manufacturing assets in the sector, reflecting the physical scale required to bring a product to market.
Market segment balance sheet capitalization - Pharma psycho
Pharmaceutical development, as the BCap_Seg chart shows, requires research-intensive rather than capital-intensive investments in the industrial sense. Avadel Pharmaceuticals, which focuses on treating CNS disorders, invests in clinical research rather than in plant construction.
Book value of all companies included in the broad market index - GURU.Markets
Avadel Pharmaceuticals' book value is primarily derived from the intellectual property and manufacturing processes associated with its narcolepsy drug. It reflects the capital invested in creating a unique tangible product and the infrastructure for its commercialization.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - AVDL
Avadel Pharmaceuticals is a pharmaceutical company. Its book value is small. Its market capitalization is determined by expectations for its key drug. The MvsBCap chart will react sharply to FDA news, patent decisions, and product launch announcements, as these determine the company's entire future for a single product.
Market to book capitalization ratio in a market segment - Pharma psycho
Avadel Pharmaceuticals is a biopharmaceutical company focused on treating sleep disorders. Its value is closely tied to the commercial success of its lead drug. The chart shows how investors value the market potential of this product, relative to the company's total assets.
Market to book capitalization ratio for the market as a whole
Avadel Pharmaceuticals is a pharmaceutical company focused on treating sleep disorders. Its valuation is heavily dependent on the success of its flagship drug. This chart illustrates how market value in the pharmaceutical industry can fluctuate dramatically based on regulatory decisions and clinical trial data, rather than book value.
Debts of the company, segment and market as a whole
AVDL - Company debts AVDL
Avadel Pharmaceuticals uses capital to commercialize its lead drug and conduct further clinical trials. Bringing a new pharmaceutical product to market is an extremely costly process, requiring investments in marketing and manufacturing. This chart shows the company's financial strategy as it moves from development to full-scale sales.
Market segment debts - Pharma psycho
Avadel Pharmaceuticals is a biopharmaceutical company focused on treating sleep disorders. The process of bringing a new drug to market, from clinical trials to marketing, requires significant financial investment. This chart provides insight into how the company manages its capital to commercialize its key product.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio AVDL
Avadel Pharmaceuticals is a biopharmaceutical company specializing in sleep disorders. The chart shows its financial structure. For a company whose success depends largely on a single key drug, debt management requires particular care. It reflects risks associated with commercial launches, competition, and patent protection.
Market segment debt to market segment book capitalization - Pharma psycho
Avadel Pharmaceuticals is a pharmaceutical company specializing in sleep disorders. This pharmaceutical industry chart reflects how companies finance clinical trials and the launch of new products. It provides context for assessing the company's financial strategy during the commercialization of its key drug.
Debt to book value of all companies in the market
Avadel Pharmaceuticals is a pharmaceutical company. Its funding depends on the success of its developments. This chart reflects the overall risk appetite in the economy. For a company in this industry, it helps understand how its funding model aligns with the overall market situation and investor confidence in its products.
P/E of the company, segment and market as a whole
P/E - AVDL
This chart from Avadel Pharmaceuticals, a company that developed a drug to treat narcolepsy, reflects investor expectations for its commercial launch. The indicator's dynamics demonstrate the market's confidence that the new drug will capture significant market share and become the company's primary profit driver for years to come.
P/E of the market segment - Pharma psycho
This chart shows the average P/E valuation for the pharmaceutical industry where Avadel is launching a new product. Comparing the company's P/E to this average helps understand how the market views the commercial potential of its narcolepsy drug relative to other pharmaceutical assets and companies.
P/E of the market as a whole
Avadel Pharmaceuticals is a biopharmaceutical company focused on developing treatments for sleep disorders, particularly narcolepsy. Its success hinges on the approval and commercial launch of a key product. This chart, reflecting investor risk appetite, shows how willing the market is to bet on a single drug that could become a blockbuster.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company AVDL
Avadel Pharmaceuticals is a biopharmaceutical company focused on the treatment of sleep disorders, particularly narcolepsy. The chart shows investor expectations for the commercial success of its lead drug. Future revenue depends on whether it can capture significant market share from existing treatments.
%20P%2FE%20AVDL&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-AVDL&v=1772592820826 "Chart of the company's future (projected) P/E AVDL")
Future (projected) P/E of the market segment - Pharma psycho
Avadel Pharmaceuticals is a biopharmaceutical company specializing in drugs for the treatment of central nervous system disorders, particularly narcolepsy. The chart shows average profitability expectations for the sector. It helps understand the market's confidence in the commercial success of its flagship product and its ability to capture market share.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-psycho&v=1772592820855 "Future (projected) P/E graph of the market segment - Pharma psycho")
Future (projected) P/E of the market as a whole
Avadel Pharmaceuticals is a biopharmaceutical company focused on treating sleep disorders, particularly narcolepsy. Its lead product offers a unique dosing regimen. This market sentiment chart shows how willing investors are to invest in companies with a single key drug, even if it targets a significant market.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772592820889 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit AVDL
Avadel Pharmaceuticals is a biopharmaceutical company specializing in the development of drugs for the treatment of central nervous system disorders. Its financial performance depends on the success of clinical trials and subsequent commercialization. This chart shows the company's path from R&D investment to potential profitability from the sale of a unique drug.
Profit of companies in the market segment - Pharma psycho
Avadel Pharmaceuticals is a biopharmaceutical company focused on the treatment of sleep disorders, particularly narcolepsy. Its key product offers a novel dosing regimen to improve patients' quality of life. This chart reflects overall profitability in the psychopharmacology sector, where innovations focused on patient convenience can be a significant competitive advantage.
Overall market profit
Avadel Pharmaceuticals is a biopharmaceutical company specializing in the treatment of sleep disorders. Its success depends on the commercialization of its lead drug and its market competition. This process is determined by clinical and marketing factors, not the overall economic situation, as illustrated by this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company AVDL
Avadel Pharmaceuticals is a biopharmaceutical company whose key product is designed to treat narcolepsy, a chronic neurological disorder. The company's future profitability depends on the successful launch and commercialization of this drug. This chart reflects analyst expectations for the market share Avadel will be able to capture from competitors.
%20profit%20of%20the%20company%20AVDL&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-AVDL&v=1772592821009 "Graph of future (projected) profit of the company AVDL")
Future (predicted) profit of companies in the market segment - Pharma psycho
Avadel Pharmaceuticals is a biopharmaceutical company focused on the treatment of sleep disorders, particularly narcolepsy. Its key drug is a novel, once-daily formulation. Its success hinges on its commercial launch. This chart shows revenue expectations for the pharmaceutical sector, providing context for assessing Avadel's potential in the CNS market.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-psycho&v=1772592821011 "Graph of future (predicted) profits of companies in a market segment - Pharma psycho")
Future (predicted) profit of the market as a whole
Avadel Pharmaceuticals is a biopharmaceutical company specializing in sleep disorders. Its commercial success depends on the sales and market acceptance of its products. This economic outlook impacts the overall solvency of the healthcare system and the willingness of insurers to cover new drugs.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772592821016 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - AVDL
Avadel Pharmaceuticals is a biopharmaceutical company focused on the treatment of sleep disorders, particularly narcolepsy. Revenue depends on the success of its key drug. This chart shows how investors assess its commercial potential against the competition. Its dynamics are a barometer of market expectations.
P/S market segment - Pharma psycho
Avadel Pharmaceuticals is a biopharmaceutical company focused on treating central nervous system disorders. Their flagship drug, designed for narcolepsy, offers significant improvements over existing treatments. This chart reflects the industry's average revenue estimates, helping to assess the commercial potential of Avadel's developments.
P/S of the market as a whole
Avadel Pharmaceuticals is a biopharmaceutical company specializing in drugs for the treatment of central nervous system disorders, particularly narcolepsy. This chart emphasizes that the company's valuation is based on the expected commercial success of its key product, making comparisons with the average market valuation based on revenue not entirely relevant.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company AVDL
Avadel Pharmaceuticals is a biopharmaceutical company focused on the treatment of sleep disorders, particularly narcolepsy. Estimating future revenue is critical for the company, especially after the approval of its key drug. The chart reflects investor expectations regarding the speed of commercialization of this product, its ability to compete in the market, and its potential to become a new standard of care.
%20P%2FS%20AVDL&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-AVDL&v=1772592821116 "The graph of the company's future (projected) P/S AVDL")
Future (projected) P/S of the market segment - Pharma psycho
Avadel Pharmaceuticals is a biopharmaceutical company specializing in the treatment of central nervous system disorders. Its key product is designed to treat narcolepsy. This chart reflects how investors view the company's future revenues relative to the pharmaceutical sector. It demonstrates the market's confidence in the commercial potential of its drug and its ability to compete in the narcolepsy market.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-psycho&v=1772592821119 "Future (projected) P/S market segment graph - Pharma psycho")
Future (projected) P/S of the market as a whole
Avadel Pharmaceuticals is a biopharmaceutical company focused on treating sleep disorders. Its success depends on the commercialization of a single key drug. In the overall revenue expectations pictured in the chart, Avadel represents a biotech company with a specific product targeting a large market.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772592821145 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales AVDL
This chart illustrates the revenue of Avadel Pharmaceuticals, a biopharmaceutical company focused on the treatment of sleep disorders, particularly narcolepsy. Revenue is generated from sales of its flagship product. Growth directly reflects the success of its market launch, acceptance by the medical community, and the increasing number of patients receiving the therapy.
Sales of companies in the market segment - Pharma psycho
Avadel Pharmaceuticals is a biopharmaceutical company focused on the treatment of sleep disorders. Its revenue depends on the success of its flagship product, LUMRYZ, for the treatment of narcolepsy. Its sales mix will reflect how successfully the company competes in this market and gains market share from existing treatments.
Overall market sales
Avadel Pharmaceuticals is a biopharmaceutical company focused on treating sleep disorders. Its success hinges on the approval and commercial launch of its lead drug. This overall economics chart reveals little about the company's prospects, as its fate is being decided in doctors' offices and regulatory agencies, not in the consumer market.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company AVDL
Avadel Pharmaceuticals is a biopharmaceutical company focused on the treatment of sleep disorders, particularly narcolepsy. Its future revenue depends on the successful commercial launch of a new drug. This chart illustrates analyst sales expectations for this product, reflecting their assessment of its competitiveness and the size of the target market for narcolepsy patients.
%20sales%20of%20the%20company%20AVDL&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-AVDL&v=1772592821167 "Schedule of future (projected) sales of the company AVDL")
Future (projected) sales of companies in the market segment - Pharma psycho
Avadel Pharmaceuticals is a biopharmaceutical company specializing in the treatment of sleep disorders, particularly narcolepsy. This chart shows the outlook for the pharmaceutical market. Is growth expected in the central nervous system disorder segment? This helps assess the overall potential of the niche in which Avadel operates.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-psycho&v=1772592821191 "Schedule of future (projected) sales of companies in the market segment - Pharma psycho")
Future (projected) sales of the market as a whole
Avadel Pharmaceuticals is a biopharmaceutical company specializing in drugs for the treatment of central nervous system disorders. The company's success depends on the approval and commercial launch of its key product. The need for treatments for neurological diseases is not dependent on economic cycles, so this schedule is not a significant factor for Avadel's business.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772592821209 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality AVDL
Avadel Pharmaceuticals is a biopharmaceutical company focused on the treatment of sleep disorders, particularly narcolepsy. This chart shows its financial position as it moves toward commercialization of a new drug. Profitability depends on regulatory approval and the successful launch of a product that could offer significant advantages over existing treatments.
Market segment marginality - Pharma psycho
Avadel Pharmaceuticals plc is a pharmaceutical company specializing in drugs for the treatment of sleep disorders, particularly narcolepsy. Its profitability depends on the commercial success of its flagship product, its pricing, and market competition. This chart shows the financial performance of a company focused on the launch and promotion of its flagship product.
Market marginality as a whole
Avadel Pharmaceuticals is a biopharmaceutical company focused on the treatment of sleep disorders. Its commercial success depends on regulatory approval and market acceptance of its new drug. This gross margin chart reflects the economic environment that influences drug pricing and the willingness of insurers to cover new treatments.
Employees in the company, segment and market as a whole
Number of employees in the company AVDL
Avadel Pharmaceuticals is a biopharmaceutical company focused on treating sleep disorders. Following the approval of its key drug, the company is actively hiring a commercial team. This chart illustrates the transformation from an R&D company to a commercial organization, which requires a significant increase in staff to launch and market the product.
Share of the company's employees AVDL within the market segment - Pharma psycho
Avadel Pharmaceuticals is a biopharmaceutical company focused on the treatment of sleep disorders, particularly narcolepsy. Following the approval of its flagship drug, the company is actively hiring for its commercialization. This graph shows the company's labor market share, and its growth may indicate a successful product launch and expansion of the commercial team.
Number of employees in the market segment - Pharma psycho
Avadel Pharmaceuticals is a biopharmaceutical company focused on the treatment of sleep disorders, particularly narcolepsy. This chart shows the company's presence in the psychopharmaceuticals sector. Developing a drug with a unique dosing regimen that improves patients' quality of life is a key strategy for Avadel to gain market share in this competitive market.
Number of employees in the market as a whole
Avadel Pharmaceuticals is a biopharmaceutical company focused on the treatment of sleep disorders, particularly narcolepsy. The growth of its commercial and research teams is directly related to the launch of a new drug. The hiring dynamics here, unlike the overall employment in this chart, represent a success story in a narrow therapeutic niche.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company AVDL (AVDL)
Avadel Pharmaceuticals is a biopharmaceutical company. This chart shows how the market values their approved drug. The company's value is concentrated in a single product. The high market capitalization per employee reflects the sales potential of this drug, managed by a small commercial team, and the value of their intellectual property.
%20of%20the%20company%20AVDL%20(AVDL)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-AVDL-AVDL&v=1772592821360 "Chart of market capitalization per employee (in thousands of dollars) of the company AVDL (AVDL)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma psycho
Avadel Pharmaceuticals (AVDL) is a biopharmaceutical company whose lead product (LUMRYZ) is designed to treat narcolepsy (severe daytime sleepiness). This chart shows the industry average cost per employee. It helps assess how the market values the commercial launch of their key drug per employee.
%20by%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-psycho&v=1772592821385 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma psycho")
Market capitalization per employee (in thousands of dollars) for the overall market
Avadel Pharmaceuticals is a biopharmaceutical company focused on treating sleep disorders. Its value depends on the success of its key drug. The chart shows a high valuation per employee, which is typical for biotech companies at the commercialization stage. The market evaluates the sales potential and patent protection of the scientific team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772592821404 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company AVDL (AVDL)
Avadel is a pharmaceutical company focused on drugs for the treatment of sleep disorders (narcolepsy). This chart shows how successfully the company is commercializing its key drug. It reflects how much net profit the team generates from sales of this niche product, covering R&D and marketing costs.
%20Chart%20AVDL%20(AVDL)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-AVDL-AVDL&v=1772592821430 "Company Profit Per Employee (in thousands of dollars) Chart AVDL (AVDL)")
Profit per employee (in thousands of dollars) in the market segment - Pharma psycho
Avadel (AVDL) is an R&D biotech company (approved drug Lumryz for narcolepsy). This chart shows the benchmark for "Pharma" (R&D). The average profit per employee in this sector (biotech) is high. The benchmark reflects a "one-hit wonder": the sector spends millions on R&D, and a single successful orphan drug recoups all costs.
%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-psycho&v=1772592821498 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma psycho")
Profit per employee (in thousands of dollars) for the market as a whole
Avadel Pharmaceuticals is a biopharmaceutical company whose lead product (Lumryz) is designed to treat narcolepsy (a competitor to HRMY). It is a single-product company. This chart shows how successfully the company's commercial team is bringing this new drug to market to cover R&D and marketing costs per employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772592821526 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee AVDL (AVDL)
Avadel Pharmaceuticals is a biopharmaceutical company whose success depends on the commercialization of its developments. This chart illustrates the potential return on investment in research. A sharp increase in revenue per employee after the launch of a new drug will reflect its market success and the high value created by the research team.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-AVDL-AVDL&v=1772592821552 "Sales chart per company employee AVDL (AVDL)")
Sales per employee in the market segment - Pharma psycho
Avadel Pharmaceuticals is a biotech focused on the treatment of sleep disorders, particularly narcolepsy. Their flagship drug is LUMRYZ. This chart shows the average revenue for the sector. For AVDL, this is an indicator of commercial success: how effective is their sales and marketing team in promoting this specialized drug in a competitive market?
Sales per employee for the market as a whole
Avadel Pharmaceuticals is a biopharmaceutical company focused on the treatment of sleep disorders, particularly narcolepsy. Following the approval of its key drug, the company has entered the commercialization phase. This chart shows how effectively their sales and marketing team is communicating the product to patients.
Short shares by company, segment and market as a whole
Shares shorted by company AVDL (AVDL)
Avadel (AVDL) is a pharmaceutical company whose key product is designed to treat narcolepsy. The company waged a lengthy patent battle to bring its drug to market. This chart shows the number of short positions. Short positions may reflect doubts about the drug's ability to successfully compete with established drugs or concerns about new lawsuits.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-AVDL-AVDL&v=1772592821602 "Short Shares Chart for the Company AVDL (AVDL)")
Shares shorted by market segment - Pharma psycho
Avadel (AVDL) is a biopharmaceutical company specializing in the treatment of sleep disorders, particularly narcolepsy. This chart aggregates short positions across the specialty pharmaceuticals sector. It reflects investor concerns about the highly competitive narcolepsy treatment market and the risks associated with commercial launch.
Shares shorted by the overall market
Avadel (AVDL) is a biotech focused on neuroscience (narcolepsy). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk. Biotech stocks, even those with approved drugs, often sell off when general pessimism rules the market.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator AVDL (AVDL)
Avadel Pharmaceuticals (AVDL) is a biopharmaceutical company whose flagship product, Lumryz, is designed to treat narcolepsy. It's a once-daily dose. Their success hinges on a commercial launch. This chart measures hype. It shows "overbought" (above 70) on news of a successful launch or patent wins, and "oversold" (below 30) on concerns about competition.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-AVDL-AVDL&v=1772592821646 "RSI 14 indicator chart for the company's stock AVDL (AVDL)")
RSI 14 Market Segment - Pharma psycho
Avadel (AVDL) is a biotech company whose flagship product (Lumryz) is a once-nightly treatment for narcolepsy. The RSI_14_Seg for "Pharma psycho" (biotech) shows the overall sentiment. The chart helps us understand: is AVDL's volatility a reaction to their trials or is the entire sector overheated?
RSI 14 for the overall market
Avadel (AVDL) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast AVDL (AVDL)
Avadel Pharmaceuticals is a biopharmaceutical company whose key product, Lumryz, is designed to treat narcolepsy (a sleep disorder). This chart shows the average 12-month analyst forecast. It represents their collective assessment of how successfully Lumryz will compete and capture market share.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-AVDL-AVDL&v=1772592821830 "A chart showing analyst consensus forecasts for the expected stock price. AVDL (AVDL)")
The difference between the consensus estimate and the actual stock price AVDL (AVDL)
Avadel Pharmaceuticals is a pharmaceutical company focused on treating sleep disorders, particularly narcolepsy, with its drug Lumryz. This chart shows the gap between the current market valuation and analysts' target price. It highlights the potential experts see for the drug's commercial success.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-AVDL-AVDL&v=1772592821858 "A chart showing the difference between the consensus forecast and the actual stock price. AVDL (AVDL)")
Analyst consensus forecast for stock prices by market segment - Pharma psycho
Avadel Pharmaceuticals is the developer of Lumryz, a sodium oxybate drug that is taken once at night for the treatment of narcolepsy (competitors require twice-nightly dosing). This chart shows general expectations for the CNS pharmaceutical sector. It reflects whether experts believe that convenience will enable market share.
Analysts' consensus forecast for the overall market share price
Avadel Pharmaceuticals (AVDL) is a biopharmaceutical company focused on neuroscience. Their key product is a drug for the treatment of narcolepsy, a serious sleep disorder. This chart shows the overall risk appetite in the market, reflecting the degree to which investors are willing to invest in the launch and commercialization of new, niche drugs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index AVDL
Avadel Pharmaceuticals is a biopharmaceutical company focused on neuroscience. Their flagship product, Lumryz, is a once-daily treatment for narcolepsy. This chart is a barometer of their commercial launch. It likely reflects the growth rate of patients switching to their drug and their ability to capture market share from a competing (twice-daily) drug.
AKIMA Market Segment Index - Pharma psycho
Avadel Pharma (AVDL) is a single-product biotech targeting the narcolepsy market (a competitor to Jazz); the company developed LUMRYZ, the first (and only) once-daily version of a key drug. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this innovative (once-daily) R&D model (AVDL) differentiate it from the average pharma company?
The AKIM Index for the overall market
Avadel Pharmaceuticals is the company commercializing Lumryz, a drug for narcolepsy with a unique once-nightly dosage. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this product launch story in a competitive market compares to the overall economic trends affecting the pharmaceutical industry.
